Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 1;180(9):1255-1256.
doi: 10.1001/jamainternmed.2020.3188.

Uptake of Infliximab Biosimilars Among the Medicare Population

Alice J Chen  1   2 , Laura Gascue  1 , Rocio Ribero  1 , Karen Van Nuys  1   2
Affiliations

Uptake of Infliximab Biosimilars Among the Medicare Population

Alice J Chen et al. JAMA Intern Med. .

Abstract

This cross-sectional study uses Medicare data to examine the uptake of Inflectra and Renflexis, and investigates physician prescribing behavior in switching between biologic and biosimilar versions.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Chen, Gascue, Ribero, and Van Nuys reported support from the Leonard D. Schaeffer Center for Health Policy & Economics during the conduct of the study and outside the submitted work. Dr Chen additionally reported grant funding from the National Institutes of Health during the conduct of the study, and personal fees from Amgen, Inc, outside the submitted work.

Figures

Figure 1.
Figure 1.. Infliximab Biosimilar Penetration and Relative Reimbursement in Medicare Part B
Q indicates quarter.
Figure 2.
Figure 2.. Adoption Patterns Among Physicians and Patients Using Biosimilar Infliximab
See this image and copyright information in PMC

Comment in

References

    1. Kozlowski S, Birger N, Brereton S, et al. . Uptake of the biologic filgrastim and its biosimilar product among the Medicare population. JAMA. 2018;320(9):929-931. doi:10.1001/jama.2018.9014 - DOI - PMC - PubMed
    1. Chen AJ, Ribero R, Van Nuys K. Provider differences in biosimilar uptake in the filgrastim market. Am J Manag Care. 2020;26(5):208-213. doi:10.37765/ajmc.2020.42786 - DOI - PubMed
    1. Food and Drug Administration Biosimilar and Interchangeable Biologics: More Treatment Choices. March 2020. https://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchang.... Accessed May 2020. .
    1. Cohen H, Beydoun D, Chien D, et al. . Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2017;33(12):2160-2172. doi:10.1007/s12325-016-0431-5 - DOI - PMC - PubMed
    1. Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019;25(1):102-112. doi:10.18553/jmcp.2019.25.1.102 - DOI - PMC - PubMed

Publication types

MeSH terms